Collaboration to Develop Diagnostic Products

(Tel Aviv, Israel). Using its genomic platform and other proprietary computational tools, Compugen is expected to provide Biosite with comprehensive data on several gene targets to be nominated by BioSite.

Under the terms of the agreement, Compugen gives Biosite an exclusive license to use the selected Compugen targets for immunoassay-based diagnostic applications. In return, Compugen is to receive milestone payments and royalties from the sales of each diagnostic product emerging from the alliance. Compugen retains the exclusive right to pursue further development in the therapeutic field, and Biosite will be entitled to receive from Compugen any milestone payments and royalties arising from a successful therapeutic application.

This collaboration combines Biosite's expertise in rapid, high-affinity antibody development and commercialization of proprietary testing platforms, consisting of both individual diagnostic markers and panels of markers, with Compugen's discovery capabilities. This discovery process relies on the comprehensive predictive analysis of the human proteome provided by the company's genomic platform. The result of this analysis is utilized with various discovery engines, each designed to identify novel proteins with specific characteristics from the vast numbers predicted by the discovery process.

"We hope that this partnership will enable access to novel markers in areas of strategic focus to Biosite that will lead to new product opportunities for us,” stated Gunars Valkirs, Ph.D., senior vice president, discovery, at BioSite.

"We are excited about the opportunity to collaborate with BioSite, a leading provider of rapid diagnostic products and antibody-development technologies,” said Mor Amitai, president and CEO of Compugen.





Related Links:
Compugen
BioSite